Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.

ABSTRACT:

Background

Pulmonary lymphoepithelioma-like carcinoma (LELC) exhibits a unique immune microenvironment, including high PD-L1 expression and abundant infiltrating-immune cells. However, the availability of PD-1/PD-L1 inhibitors in patients with LELC is still not determined.

Methods

A total of 36 cases of pulmonary LELC treated with PD-1/PD-L1 inhibitors were reviewed, including 10 cases from our institute and 26 cases included from the literature. The Kaplan-Meier method and log-rank test were utilized to analyze the survival outcomes of LELC patients receiving immunotherapy, and the factors related to immunotherapy response were further examined.

Results

Of the 10 patients from our institute, the median age was 53.5 years, adrenal glands and distant lymph nodes were t

SUBMITTER: Zhou N 

PROVIDER: S-EPMC9763302 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature